 SYDNEY, AUSTRALIA, Jan. 31, 2022 GLOBE NEWSWIRE -- Immutep Limited ASX: IMM; NASDAQ: IMMP Immutep or the Company, a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune diseases, announced today that Immutep CEO Marc Voigt has been invited to participate in the following investor conferences scheduled to take place in February 2022. 